Next 10 |
2024-05-13 10:30:04 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for ARWR on May 13, 2024 08:34AM ET. The previous analyst recommendation was Equal-Weight. ARWR was trading at $22.39 at issue of the analyst recommendation. The overall analyst consensus : ...
2024-05-12 11:00:00 ET More on Acadia Pharma, BridgeBio Pharma, etc. ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript ACADIA Pharmaceuticals Inc. 2024 Q1 - Results - Earnings Call Presentation Rocket Pharmaceuticals: Cautiously Optimistic (Rating U...
2024-05-09 21:23:07 ET Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2024 Earnings Conference Call May 09, 2024, 04:30 PM ET Company Participants Vince Anzalone - VP, IR Chris Anzalone - President and CEO Bruce Given - Chief Medical Scientist James Hamilton - Chi...
2024-05-09 16:01:55 ET More on Arrowhead Pharmaceuticals Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade) Arrowhead Pharmaceuticals Q2 2024 Earnings Preview Arrowhead Pharmaceuticals secures $50M milestone from Royalty Pharma See...
- Conference Call and Webcast Today, May 9, 2024, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 second quarter ended March 31, 2024. The Company is hosting a conference call today, May 9, 2024, at 4:30 p.m. ET to discu...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
2024-05-09 05:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-08 11:49:59 ET More on Arrowhead Pharmaceuticals Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade) Arrowhead Pharmaceuticals secures $50M milestone from Royalty Pharma Arrowhead Pharmaceuticals jumps amid takeover speculation ...
2024-05-02 16:17:14 ET More on Arrowhead Pharmaceuticals Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade) Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2024 Earnings Call Transcript Arrowhead Pharmaceuticals jumps amid takeover speculation ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX). This milestone was triggered after the completion of enrollment of the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran, being conducted by Amgen (NASD...
News, Short Squeeze, Breakout and More Instantly...
Arrowhead Pharmaceuticals Inc. Company Name:
ARWR Stock Symbol:
NASDAQ Market:
2024-05-13 10:30:04 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for ARWR on May 13, 2024 08:34AM ET. The previous analyst recommendation was Equal-Weight. ARWR was trading at $22.39 at issue of the analyst recommendation. The overall analyst consensus : ...
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly fina...
- Conference Call and Webcast Today, May 9, 2024, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 second quarter ended March 31, 2024. The Company is hosting a conference call today, May 9, 2024, at 4:30 p.m. ET to discu...